[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"Nanjing Legend Biotech Co.\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":89},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,3,0,[8,41,67],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":4,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":30,"lastUpdatePostDateStruct":31,"startDateStruct":34,"completionDateStruct":35,"leadSponsor":37,"locationsCount":40},"100618411","phase-1-a-study-of-lucar-g79d-in-subjects-with-relapsedrefractory-systemic-lupus-erythematosus-rr-sle-and-idiopathic-inflammatory-myopathies-rr-iim-100618411",false,"NCT07331272","A Study of LUCAR-G79D in Subjects With Relapsed\u002FRefractory Systemic Lupus Erythematosus (r\u002Fr SLE) and Idiopathic Inflammatory Myopathies (r\u002Fr IIM)","An Open-label Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of LUCAR-G79D in Subjects With Relapsed\u002FRefractory Systemic Lupus Erythematosus (r\u002Fr SLE) and Idiopathic Inflammatory Myopathies (r\u002Fr IIM)","Inclusion Criteria:\n\n1. Subjects voluntary agreement to provide written informed consent.\n2. Aged 18 to 70 years, either sex.\n3. Adequate organ function meet screening criteria.\n4. Positive test for cluster of differentiation antigen 19 (CD19).\n\nSLE:\n\n* Have been diagnosed of SLE at least 6 months before screening.\n* At screening, antinuclear antibody, and\u002For anti-dsDNA antibody, and\u002For anti-Smith antibody should be positive.\n* Fulfill relapsed\u002Frefractory SLE conditions.\n\nIIM:\n\n* Have been diagnosed of IIM before screening.\n* Positive test for myositis-associated antibodies or myositis-specific antibodies at screening.\n* Fulfill relapsed\u002Frefractory IIM conditions.\n\nExclusion Criteria:\n\n1. Active infections such as hepatitis and tuberculosis.\n2. Other autoimmune diseases.\n3. Serious underlying diseases such as tumor, uncontrolled diabetes.\n4. Female subjects who were pregnant, breastfeeding.\n5. Those with a history of major organ transplantation.","ALL","18 Years","70 Years",{"count":20,"type":21},38,"ESTIMATED","INTERVENTIONAL",[24],"PHASE1","This is a prospective, single-arm, open-label and dose-escalation investigator initialed study to evaluate LUCAR-G79D in adult subjects with r\u002Fr SLE and r\u002Fr IIM.",[27,28],"Systemic Lupus Erythematosus (SLE)","Idiopathic Inflammatory Myopathies(IIM)","RECRUITING","2026-01-29",{"date":32,"type":33},"2026-02-02","ACTUAL",{"date":30,"type":33},{"date":36,"type":21},"2030-01-31",{"name":38,"class":39},"Nanjing Legend Biotech Co.","INDUSTRY",5,{"id":42,"slug":43,"hasResults":11,"nctId":44,"briefTitle":45,"officialTitle":46,"acronym":4,"eligibilityCriteria":47,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":48,"targetDuration":4,"studyType":22,"phases":50,"briefSummary":52,"conditions":53,"keywords":55,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":58,"lastUpdatePostDateStruct":59,"startDateStruct":61,"completionDateStruct":63,"leadSponsor":65,"locationsCount":66},"100600636","lcar-f33s-in-treatment-of-relapsedrefractory-multiple-myeloma-100600636","NCT07100067","LCAR-F33S in Treatment of Relapsed\u002FRefractory Multiple Myeloma","A Clinical Study to Evaluate the Safety, Tolerance and Efficacy of LCAR- F33S Cell Therapy in Patients With Relapsed\u002FRefractory Multiple Myeloma.","Inclusion Criteria:\n\n* Subjects voluntarily participate in clinical research.\n* Age ≥18 years old.\n* Eastern Cooperative Oncology Group (ECOG) score 0-2.\n* Examination evidence of initial diagnosis of MM according to IMWG diagnostic criteria.\n* Measurable lesions were present.\n* Subjects have received treatment with one PI, one IMiD and a CD38 monoclonal antibody.\n* Subjects have received at least three previous lines of multiple myeloma therapy, each with at least one complete therapy cycle, unless the best response to the therapeutic regimen was documented as disease progression (PD confirmed according to IMWG criteria).\n* Expected survival ≥3 months.\n* Clinical laboratory values in the screening period meet criteria.\n\nExclusion Criteria:\n\n* Received previous therapy targeting FcRH5 targets.\n* Prior antineoplastic therapy and meet exclusion criteria (before apheresis);\n* Subjects had Plasma cell leukemia, Waldenstrom macroglobulinemia, POEMS syndrome, or primary AL amyloidosis at the time of screening.\n* Subjects who were positive for any of HBsAg, HBV DNA, HCV-Ab, HCV RNA, and HIV-Ab;\n* Life-threatening allergic reactions, hypersensitivity reactions, or intolerance to CAR-T cell formulations or their excipients, including DMSO, are known.\n* Serious underlying diseases were present.\n* Female subjects who were pregnant, breastfeeding, or planning to become pregnant while participating in this study or within 1 year of receiving study treatment.\n* Also enrolled in other clinical studies.",{"count":49,"type":21},35,[51],"NA","A prospective, single-arm, open-label dose-exploration and expansion study to evaluate the safety, tolerability, pharmacokinetics, and antitumor efficacy characteristics of LCAR-F33S in patients with relapsed\u002Frefractory multiple myeloma(Investigator-initiated Study).",[54],"Relapsed\u002FRefractory Multiple Myeloma(MM)",[56,57],"multiple myeloma","Relapsed\u002FRefractory multiple myeloma","2025-12-25",{"date":60,"type":33},"2025-12-29",{"date":62,"type":33},"2025-09-16",{"date":64,"type":21},"2029-11-20",{"name":38,"class":39},4,{"id":68,"slug":69,"hasResults":11,"nctId":70,"briefTitle":71,"officialTitle":72,"acronym":4,"eligibilityCriteria":73,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":74,"targetDuration":4,"studyType":22,"phases":76,"briefSummary":78,"conditions":79,"keywords":4,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":81,"lastUpdatePostDateStruct":82,"startDateStruct":84,"completionDateStruct":86,"leadSponsor":88,"locationsCount":40},"100600252","early-phase-1-a-study-of-lucar-dks1-in-subjects-with-relapsedrefractory-autoimmune-diseases-100600252","NCT07095075","A Study of LUCAR-DKS1 in Subjects With Relapsed\u002FRefractory Autoimmune Diseases","An Open-label Clinical Study to Evaluate Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of LUCAR-DKS1 in Subjects With Relapsed\u002FRefractory Autoimmune Diseases (r\u002Fr AID)","* Inclusion Criteria:\n\n  1. Subjects voluntary agreement to provide written informed consent.\n  2. Aged 18 to 70 years, either sex.\n  3. Clinical laboratory values meet screening criteria.\n  4. Positive test for CD19 and\u002F or BCMA\n\nSLE:\n\n* Meets at least 1 classification criteria≥6 months for SLE.\n* At screening, antinuclear antibody, and\u002For anti-dsDNA antibody, and\u002For anti-Smith antibody should be positive.\n* Fulfill relapsed\u002Frefractory SLE conditions.\n\nAAV:\n\n* Meets the 2022 ACR\u002FEULAR classification criteria for AAV.\n* Positive test for anti-MPO or p-ANCA or anti-PR3 or anti-MPO antibodies at screening.\n* Fulfill relapsed\u002Frefractory AAV conditions.\n\nSSc:\n\n* Meets the 2013 ACR\u002FEULAR classification criteria for SSc.\n* At screening, mRSS is higher than 10.\n* Fulfill relapsed\u002Frefractory SSc conditions.\n\nIIM:\n\n* Meets 2017 EULAR\u002FACR classification criteria for IIM.\n* Positive test for myositis-associated antibodies or myositis-specific antibodies at screening.\n* Fulfill relapsed\u002Frefractory IIM conditions. SjS：\n* Meets the 2016 ACR\u002FEULAR diagnostic criteria for SjS.\n* Positive test for anti-SSA and\u002For anti-SSB antibodies at screening.\n* Fulfill relapsed\u002Frefractory SjS conditions.\n\nExclusion Criteria:\n\n1. Active infections such as hepatitis and tuberculosis.\n2. Other autoimmune diseases.\n3. Serious underlying diseases such as tumor, uncontrolled diabetes.\n4. Female subjects who were pregnant, breastfeeding.\n5. Those with a history of major organ transplantation.\n6. Have received autologous cell therapy of any target before.",{"count":75,"type":21},36,[77],"EARLY_PHASE1","This is a prospective, single-arm, open-label and dose-escalation Investigator Initialed study to evaluate LUCAR-DKS1 in adult subjects with relapsed\u002Frefractory autoimmune diseases.",[80],"Relapsed\u002FRefractory Autoimmune Diseases","2025-12-09",{"date":83,"type":33},"2025-12-10",{"date":85,"type":33},"2025-10-14",{"date":87,"type":21},"2029-12-31",{"name":38,"class":39},""]